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For decades, basic research on the underlying mechanisms of nociception has held 
promise to translate into efficacious treatments for patients with pain. Despite 
great improvement in the understanding of pain physiology and pathophysiology, 
translation to novel, effective treatments for acute and chronic pain has however 
been limited, and they remain an unmet medical need. In this opinion paper bring-
ing together pain researchers from very different disciplines, the opportunities and 
challenges of translational pain research are discussed. The many factors that may 
prevent the successful translation of bench observations into useful and effective 
clinical applications are reviewed, including interspecies differences, limited va-
lidity of currently available preclinical disease models of pain, and limitations of 
currently used methods to assess nociception and pain in non- human and human 
models of pain. Many paths are explored to address these issues, including the 
backward translation of observations made in patients and human volunteers into 
new disease models that are more clinically relevant, improved generalization by 
taking into account age and sex differences, and the integration of psychobiology 
into translational pain research. Finally, it is argued that preclinical and clinical 
stages of developing new treatments for pain can be improved by better preclini-
cal models of pathological pain conditions alongside revised methods to assess 
treatment- induced effects on nociception in human and non- human animals.
Significance: For decades, basic research of the underlying mechanisms of nociception has 
held promise to translate into efficacious treatments for patients with pain. Despite great 
improvement in the understanding of pain physiology and pathophysiology, translation to 
novel, effective treatments for acute and chronic pain has however been limited, and they 
remain an unmet medical need.
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1 |  INTRODUCTION
Understanding the neurobiology of pain is of high interest 
due to the enormous burden of pain for patients and society. 
There have been very few major breakthroughs leading to ef-
fective interventions or treatments for acute and chronic pain 
in recent times. Indeed, most available interventions have 
been in use for decades and provide limited long- term effects. 
Furthermore, side effects, drug interactions (e.g. analgesics/
co- analgesics) and drug misuse present a major challenge for 
successful pain management.
Without doubt, accumulated basic knowledge regarding 
the mechanisms underlying pain perception is today much 
more refined than what was available two decades ago due 
to the fascinating opportunities and breakthrough meth-
odologies in neuroscience. The specific understanding of 
the animal nociceptive system, as well insight into mal-
adaptive processes that underlie pathological conditions in 
non- human animals, has advanced significantly. However, 
as a research community, we must be critical of the lack 
of translation between instrumental findings about noci-
ceptive processing in non- human animals and proposed 
clinical intervention strategies in patients. At present, the 
clinical relevance of the different pathophysiological pro-
cesses that have been characterized in preclinical models 
of pain remains largely unknown. Recently, Yezierski and 
Hansson outlined a number of concerns that could poten-
tially explain the lack of progress in the field of transla-
tional pain research, specifically regarding inflammatory 
and neuropathic pain explored using behavioural assays 
(Yezierski & Hansson,  2018). The challenges of transla-
tional research on neuropathic pain were also reviewed 
by Attal and Bouhassira (2019). A lack of relevant pain 
models and assessment strategies, species differences and 
repeated failures of clinical trials were just some of the im-
portant factors listed.
Prevention of pain in general is a critical clinical issue 
that has been taken up by the IASP and EFIC as the Global 
year theme 2020 (https://www.iasp- pain.org/Globa lYear). 
Challenges in translational pain research have been addressed 
in acute postoperative pain and prevention of chronic pain 
after surgery (Pogatzki- Zahn et al., 2018). Although multiple 
neurophysiological mechanisms that could cause persistence 
of pain have been decoded in preclinical studies, the preven-
tion of chronic pain in patients remains an area of unmet clin-
ical need.
The leadership of the European Pain Federation recog-
nized the need for directions and policies of translational 
pain research, and installed in 2017 a transdisciplinary 
working group on translational pain research within its 
research committee, composed of preclinical and clini-
cal pain researchers with different backgrounds: anaes-
thesiology, biomedical engineering, neurophysiology, 
neuropharmacology, experimental psychology and neu-
rology. This paper reflects the outcome of the discussions 
within this specific working group. The aim of the pres-
ent paper is to clarify core concepts and definitions, and 
to discuss the opportunities as well as the challenges of 
translational pain research exemplified within the 2020 
Global Year Against Pain (GYAP) theme. The span across 
translational concepts from bench to man and the interac-
tions between somatosensory biology and psychobiology 
is considered (Figure  1). An important strength of trans-
lational pain research is collaboration across the many 
different disciplines involved. Methodological details are 
provided within experimental human research to illustrate 
current limitations and potentials for backward translation 
into mechanistic studies with improved clinical relevance.
2 |  TRANSLATIONAL PAIN 
RESEARCH
The meaning of translational pain research may be un-
derstood differently among individuals. Considering the 
definition of translation as ‘a version in a different lan-
guage’ or ‘moving something from one place to another’, 
translational pain researchers are tasked with expressing a 
particular form of something – for example a pain state 
or targeted therapeutic strategy – that differs in certain re-
spects from other forms of the same thing. Therefore, the 
true meaning of translational medicine is open to specula-
tion. When taking into account the mechanistic adaptations 
F I G U R E  1  Translational pain research across axes consisting of 
laboratory animal to human (experimental and patients) and biological 
systems (somatosensory to psychological). Examples of disciplines 
involved in translational pain research illustrate the inter- disciplinary 
approach
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that occur in a pain state, basic researchers, pain clinicians 
(including physicians, psychologists, pain nurses, physi-
otherapists and others) and even patients might assume 
and/or hope that a linear movement from bench to bedside, 
in terms of the molecular and psychosocial processes de-
scribed or pharmacotherapeutic targets defined, is achiev-
able. However, this is rarely the case. A more realistic goal 
might be to discover a novel pain pathway or circuit com-
ponent in the rodent that then provides insight regarding 
underlying circuitries and potential therapeutic targets or 
strategies in humans.
2.1 | Translating ‘pain’ at the 
laboratory bench
The translational issues that laboratory scientists face when 
conducting research to identify mechanisms contributing 
to a particular pain state are several. The first hurdle re-
lates to terminology since laboratory animals (most often, 
rats or mice), although sentient, cannot relay directly their 
pain ‘perception’. As such, basic science researchers must 
refer to ‘nociceptive behaviour’ or ‘pain related behav-
iour’. This complexity encompasses translation of an in-
ferred pain level. The process of interpreting, in awake 
animals, a result that might be symptomatic of pain is a 
major limitation, and measuring pain thresholds is chal-
lenging (Mogil,  2009; Segelcke et  al.,  2019). However, 
assessing pain in the clinic is also difficult and should 
go beyond questions about pain intensity (Pogatzki- Zahn 
et al., 2019a). It should focus on mechanisms modulating 
nociception such as the mechanisms leading to central sen-
sitization or producing endogenous pain modulation. This 
can be achieved by assessing, for example, hyperalgesia, 
temporal summation of pain or the effects of heterotopic 
noxious conditioning stimulation. Psychosocial and func-
tional impacts of pain should also be assessed carefully. 
Asking patients to score their pain using, for example, a 
visual analogue scale and distinguishing ‘sensory discrimi-
native’ versus ‘affective motivational’ components of the 
pain experience is likely an oversimplification of the pain 
experience. The more, human pain ratings are strongly af-
fected by several social and cognitive factors such as social 
desirability, context and expectations (Bingel et al., 2011; 
Deshields et al., 1995). These factors could affect both the 
subjective experience of pain and the way this pain is re-
ported using ratings.
Following surgery to induce a pain state, some aspects of 
animal behaviour will change in a manner that relates specif-
ically to the disease model and/or animal setting (e.g. num-
ber of animals in the cage, healthy or injured together, both 
sexes together). Versatile examination of species- specific be-
havioural changes and developing ethograms of animals in 
their home cages might be one future direction for transla-
tional research (Mogil, 2009; Yip et al., 2019). Clinically rel-
evant behaviours related to a given aetiology of pain should 
also be studied. For example, movement- evoked pain is clin-
ically relevant for patients after surgery (Srikandarajah & 
Gilron, 2011). In rodents, multidimensional pain assays like 
gait analysis or locomotor activity monitoring in the home 
cage or in a novel environment might represent objective cor-
relates for movement- evoked pain and its functional conse-
quences (Bree et al., 2015; Tappe- Theodor et al., 2019). The 
mechanisms underlying these behaviours are different from 
the mechanisms underlying behaviours referring to sponta-
neous pain after surgery, and the assessment paradigms differ 
accordingly (Remeniuk et al., 2015; Segelcke et al., 2019). 
Another example of complexity is the neuronal response to 
suprathreshold stimuli measured in anaesthetized animals 
(Urch & Dickenson, 2003) to provide a quantification of an 
inferred level of nociception. Interestingly, in a rat model 
of neuropathy, spinal neuronal responses to peripheral su-
prathreshold stimulation are comparable between control 
animals and animals exposed to surgery, and a difference is 
only revealed when pharmacology is applied (Matthews & 
Dickenson,  2002). The inhibitory effect of state- dependent 
drugs such as gabapentinoids (Bannister, Qu, et  al.,  2017) 
provides a focus for the mechanisms driving the affective and 
sensory pain states in this animal model of pain, and these 
mechanisms translate to the clinic (Finnerup et  al.,  2002). 
Finally, disease- and symptom- specific models need to be 
studied with the aim of identifying mechanisms related to 
specific pain states. Identifying mechanisms that drive a pain 
state opens the potential for treatment targets to be pursued 
in defined clinical settings. Together, we urgently need ad-
vances in preclinical research to translate better our findings 
to humans, specifically patients, and to provide backward 
translation of human experimental approaches into animal 
settings. One aspect that must be considered in future work 
is whether changes in behaviour or neuronal function that are 
reported after only a couple of days or weeks in animals mod-
els of pain actually relate to clinical pain conditions lasting 
months or years in patients.
2.2 | Animal and human correlates of pain
Experimentally, perceived responses to painful stimuli may 
be assessed and compared between patients with chronic pain 
and age- matched healthy human controls. Self- reports of pain 
can be vocalized and combined with objective measurements 
(for example, heart rate, blood pressure, respiratory rate, 
pupil diameter and its dynamics, reflexes, cortical evoked 
responses) although they are not nociceptive specific. Self- 
reports and physiological signs do not necessarily correlate 
and therefore physiological signs cannot be used to validate 
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the severity and complexity of pain reported by humans. The 
complexity of comparing human perceptual responses to 
painful stimuli to those inferred in animals (see previous sec-
tion) is therefore considerable. Nonetheless, this comparison 
is crucial if pain readouts are to be translated to and from 
preclinical and clinical realms. Parallel results in rodents 
and humans validate translational efforts. For example, rat 
spinal neuronal activity measured using electrophysiology 
was previously correlated with human thermal pain thresh-
olds (O’Neill et al., 2015). Similarly, Sikandar et al. (2013) 
observed a strong correlation between dorsal horn activity 
recorded in rodents and pain perception reported by humans 
exposed to thermo- nociceptive laser stimuli, indicating that 
responses of rat dorsal horn neurones can translate to human 
nociceptive processing. Restrictions associated with investi-
gating brain function were circumnavigated with the advent 
of, and advances in, the acquisition and analysis of functional 
connectivity between spatially distributed but linked brain re-
gions (Kucyi & Davis, 2015; Tracey & Mantyh, 2007). Using 
pre- clinical fMRI offers the opportunity to define neuronal 
activation patterns in rodent models of acute and chronic 
pain, to validate a potential correlation with clinical data 
(Amirmohseni et al., 2016; Jia et al., 2017; Just et al., 2019).
2.3 | Adequate mechanisms and models for 
forward translation
Key questions include ‘do basic pain mechanisms, as eluci-
dated in naïve animals, translate to those mechanisms that 
underlie the normal functioning of pain pathways in man?’ 
and ‘do data collected from animal models translate to the 
clinical domain?’ where the animal model used becomes 
pivotal. At least macroscopically, the anatomy of pain path-
ways seems to translate relatively well from rodents to hu-
mans, but what about peripheral and central mechanisms? 
Cyclooxygenase inhibition attenuates pain across species 
(Hagen & Alchin, 2020; Shamsi Meymandi et al., 2019) and 
the phenomenon of wind up, whereby a persistent barrage of 
nociceptive stimuli at the periphery results in amplified spinal 
neuronal responses, corresponds partly to temporal summa-
tion in humans (Bosma et al., 2015). Finding adequate animal 
models for forward translation is complicated by the fact that, 
in most circumstances, subacute and chronic pain states may 
be driven by more than one mechanism (e.g. peripheral sensi-
tization due to tissue inflammation, neuroimmune/microglial 
mechanisms, sensitized central mechanisms, deficient de-
scending control). Furthermore, several of these mechanisms 
may interact with each other, making it even more compli-
cated to find adequate animal models. Rodent models of joint 
degeneration have shown reduced intra- epidermal nerve 
fibre density and spinal cord microglial activation, suggest-
ing that joint degeneration induces changes in the nociceptive 
pathways that may contribute to pain (Thakur et  al.,  2012; 
Thakur et al., 2014). However, it is noteworthy that whether 
these observations directly translate to the clinical situation is 
unknown. Models of spinal cord injury may encompass neu-
ropathic and musculoskeletal pain, but emulating the clinical 
situation is complex (Nakae et al., 2011). Certainly, identify-
ing specific factors or mechanisms that are lacking in for-
ward translation is more complicated than identifying those 
present. Regardless of the experimental method of injury and 
measurement of nociception, laboratory scientists must be 
able to detect pain- like responses in a manner that translates 
to the clinical domain if a true translation is to be achieved.
2.4 | Back translation
Why back translate when sophisticated bedside techniques 
can suitably evoke and/or quantify pain? After all, human 
psychophysical studies can reveal novel aspects of particu-
lar pain mechanisms or phenomena in chronic pain patients; 
such as expanded referred pain areas (Graven- Nielsen & 
Arendt- Nielsen,  2010), facilitated temporal summation of 
pain (McPhee & Graven- Nielsen, 2019; McPhee et al., 2020; 
Staud et al., 2001), and reduced efficacy of descending in-
hibitory control system (McPhee & Graven- Nielsen,  2019; 
McPhee et  al.,  2020) or changes in somatosensory sen-
sitivity (Graven- Nielsen & Arendt- Nielsen,  2010; Rolke 
et  al.,  2006). However, back translation is vital when con-
sidering the refinement of animal models used, which itself 
relates to the pivotal ‘issue’ with forward translation; that is, 
the appropriateness of the animal model used. By substanti-
ating that a paradigm used in human psychophysical testing 
can evoke equivalent and/or measurable aspects of a nocicep-
tive response in healthy animals, the field of forward trans-
lation would progress. For example, recent evidence that a 
noxious cuff pressure paradigm activates the descending pain 
modulatory system in rats and humans has important impli-
cations for the forward translation of bench and experimental 
pain research findings to the clinic (Cummins et al., 2020).
In translational pain research, the species- difference in 
key findings is a major issue and widely discussed. Innovative 
approaches are needed and alternative species for animal ex-
perimentations may be an interesting path to follow. As an 
example, recent initiatives investigate the pain related cor-
tical neuroplastic manifestations in a pig model whose anat-
omy and physiology is closer to that of humans than rodents 
(Gigliuto et al., 2014).
3 |  FROM BENCH TO MAN
At the laboratory bench, numerous approaches may be em-
ployed to uncover novel underlying nociceptive mechanisms. 
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For example, the use of in vivo imaging of genetically- 
encoded calcium indicators has revolutionized our ability to 
sample large neuronal populations; in the periphery, dorsal 
root ganglion primary afferent neurons can be recorded in 
their thousands, revealing key functional properties at a pop-
ulation level (Kim et al., 2016; Wang et al., 2018). Higher 
temporal resolution is afforded using electrophysiological 
techniques that allow analysis of single unit activity in vivo. 
Through revealing potential sources of nociceptive signals 
in animal models of, for example, neuropathy, differences 
between peripherally and centrally driven mechanisms can 
be identified (Bannister, Qu, et al., 2017; North et al., 2019; 
Wall & Devor, 1983). Ex vivo preparations can also be ap-
plied to obtain data from intact afferent fibres intrinsic to 
nociception (Guo et  al.,  2019) and the development of an-
algesics can be facilitated by in silico techniques (Takasaki 
et al., 2018). The ultimate aim is to gain a steer on the identity 
of novel therapeutic targets that translate either to models of 
experimental pain studies in humans or to pain research and 
clinical trials in patients (Figure 2). This can appear a large 
leap when considering bench approaches. However, studying 
pain circuitry in animals is a vital step towards the identifica-
tion of such targets.
3.1 | Relevant animal models and 
clinical trials
It is possible to produce animal models of nerve damage 
(Kim & Chung, 1992), inflammation (Guzman et al., 2003), 
cartilage- loss (Bellavance & Beitz, 1996), post- surgical states 
(Bree et  al.,  2015; Brennan, 1999; Flatters, 2008; Pogatzki 
& Raja, 2003; Pogatzki- Zahn et al., 2018) and cancer states 
(Kucharczyk et al., 2020). To some extent, it is thus possible 
to produce models of pathology resembling those of patients 
with pain using specialized surgical and pharmacological ap-
proaches in animals. For example, the clinical observations 
that oxcarbazepine may be effective only in a specific sub-
group of patients with peripheral neuropathic pain displaying 
the so- called irritable nociceptor phenotype – characterized 
by hyperalgesia and allodynia (Demant et  al., 2014) – was 
successfully back- translated in a rat model of neuropathy in 
which similar effects are observed following oxcarbazepine 
treatment (Patel et al., 2019). Likewise, there are several mod-
els for musculoskeletal pain that may have clinical relevance 
(Hoheisel et al., 2013; Sluka et al., 2001). Despite this, ani-
mal model outcomes do not always translate directly to man 
and the failure of an analgesic therapy to relieve symptoms in 
a clinical trial is often attributed to the ‘poor’ animal model 
used (Gregory et al., 2013; Hill, 2000). However, failure to 
translate preclinical results into analgesic action in patients 
can also be attributable to suboptimal clinical trial designs, 
inadequate sample numbers, insufficient dosage selection for 
target engagement, or interspecies differences in pharmaco-
dynamics and/or active/inactive metabolites. Additional study 
design flaws may relate to the type of pain that is measured 
(e.g. evoked versus. spontaneous pain) (Sluka et  al.,  2013) 
or the subjective manner in which pain is assessed using 
one- dimensional ratings in humans (e.g. often relying only 
on a simple visual analogue scale based measure of the sen-
sory component of pain; Gilron et al., 2019; Pogatzki- Zahn 
et al., 2019a)). There is a requirement for preclinical research 
F I G U R E  2  Translational pain research components illustrated for selected conditions of neuropathic and post- operative pain. Outcome 
profiles of various assessment modalities is shown for animal (bench) models and human experimental pain models as well as in patients (bedside)
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to more thoroughly consider and model disease specific pain- 
related symptoms and the affective- motivational and cogni-
tive dimensions of the pain experience. These dimensions 
are highly relevant to the clinical manifestations of pain, 
often refractory to treatment, and as great or greater burden 
on patients than the sensory component of pain. This is also 
a crucial consideration regarding how pain measurements 
performed in experimental and acute pain settings can be re-
lated to assessments performed in more chronic pain settings. 
There remains a need to develop better measures for the as-
sessment of pain that are specific for experimental, acute and 
chronic pain. NRS/VAS ratings are still used extensively, 
despite many known limitations. One important topic not yet 
elucidated is the definition of the extremities of pain inten-
sity rating scales. Common definitions used across experi-
mental, acute and chronic pain are “worse pain imaginable” 
or “most intense pain tolerable”. Such descriptions are highly 
subjective and personal experiences can influence the indi-
vidual conceptualization of such endpoint anchors and thus 
ratings of pain (Becker et al., 2020; Dannecker et al., 2007; 
Yokobe et al., 2014). To circumvent such problems, cross- 
model matching procedures have been developed to con-
struct more reliable and valid verbal rating scales of clinical 
pain (Gracely, 1990; Heft et al., 1980). However, these meth-
ods are not commonly used, possibly because their applica-
tion requires time, which is often a limiting factor in clinical 
contexts. More research is needed on the definitions of scale 
endpoints related to pain ratings and how they influence the 
ratings. Regarding whether healthy volunteers use ratings 
scales differently to patients with chronic pain, there appears 
to be some relatively small differences following application 
of experimental pain stimuli (Becker et al., 2020). For differ-
ent scopes related to acute versus chronic pain and different 
chronic pain- related diseases, there are recent recommenda-
tions for outcome domain assessment (“what to measure”) 
as well as respective patient- reported and patient- relevant 
outcome measures (PROMs and PREMs, “how to measure”) 
(Pogatzki- Zahn et al., 2019a). Despite some overlap between 
the established Core Outcome Sets, many aspects have been 
considered varyingly, presumably in part due to differences 
between relevance of outcome for different (chronic) pain 
states. Placebo studies highlight the complexities surround-
ing treatment expectations (Petersen et  al.,  2014), an issue 
not often contended in animal studies.
The predictive validity of preclinical models, relating to 
the extent to which drugs work in animals compared to hu-
mans, can be improved by the development of animal mod-
els based on clinical disease presentation and pathology (i.e. 
face validity). Ideally, given the complexities of disease states 
that encompass neuropathic, inflammatory and post- surgical 
pain (Pogatzki- Zahn et al., 2018; Thakur et al., 2014), drugs 
should be screened in multiple animal models, each predic-
tive of human efficacy. This is naturally difficult because of 
differing routes of administration, pharmacokinetics, dos-
ing regimens and the varying nature of the human condition 
(itself a crucial factor; e.g. patients with knee osteoarthritis 
will often perceive their pain uniquely, and the reasons for 
this are likely multi- factorial and not fully understood). It is 
prudent to note that a laboratory animal cannot tell that it is 
experiencing pain and therefore we are limited to the inter-
pretation of so- called pain- related or nociceptive/nocifensive 
behaviours. This immediately highlights the limitation of 
sensory- evoked measures. Basic science researchers should 
discuss and draw conclusions with reference to ‘nociception’ 
(pertaining to transduction, transmission and modulation 
of a nociceptive stimulus), rather than to ‘pain’. This high-
lights the issues with translating research outputs gleaned at 
the bench, to man. Despite these considerations, there are 
several examples of successful clinical trials based on ani-
mal models. TNF- alpha antibody therapy for rheumatoid 
arthritis, along with clinical application of ziconotide, high 
concentration capsaicin (although this could also be con-
sidered a refinement of a treatment dating back to the 19th 
century (Turnbul,  1850)), and tanezumab for chronic pain, 
and monoclonal antibodies against CGRP for migraine rep-
resent some recent examples of effective translation of basic 
bench research to human therapy (Alonso- Ruiz et al., 2008; 
Backonja,  2012). Serendipity plays a role; for neuropathic 
pain, clinically available front- line drugs are borne from re-
search of anti- depressant and anti- epileptic therapies (Baidya 
et al., 2011; Sawynok et al., 1999). Of course, promising data 
collected in animal models does not necessarily translate to a 
successful clinical trial. Preclinically, tachykinin NK1 recep-
tor antagonism attenuates nociceptive responses, but no anal-
gesic response is observed clinically (Hill, 2000). Similarly, 
inhibition of low threshold activated T- type calcium channels 
that are upregulated in primary sensory neurons in preclinical 
models of chronic pain, rarely perform better than placebo 
agents in humans (Snutch & Zamponi,  2018). Such issues 
with translation highlight the complexity of the physiological 
processes that must be manipulated to produce analgesia in 
humans. There are also safety issues, underlining the failure 
of drugs including nicotine agonists and TRPV1 antagonists, 
where intolerable side effects render the relevant pharmaco-
therapies useless.
3.2 | Measuring clinically relevant 
spontaneous/ongoing pain
Modelling spontaneous or ongoing pain in rodents is a sig-
nificant challenge for preclinical research. Rats and mice 
rarely develop or exhibit behaviours indicative of spontane-
ous or ongoing pain, likely because they are prey animals 
and have evolved to hide signs of weakness or injury. Thus, 
the vast majority of preclinical pain models and research 
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relies on inducing, through experimental injury, a state of 
hypersensitivity to non- noxious and noxious stimuli (evoked 
pain), or a set of nociceptive behaviours, which manifest over 
a defined and limited period of time post- injury (e.g. hind 
paw licking and flinching in the formalin test). However, 
in the clinic, spontaneous and ongoing pain often presents 
more of a problem for patients than evoked pain and, if both 
occur, the mechanisms behind them are different (Segelcke 
et  al.,  2019). Recently, there have been some advances in 
preclinical modelling of these aspects. Notably, Porreca and 
colleagues have developed a useful behavioural paradigm for 
demonstrating and investigating ongoing pain in rodents that 
is based on conditioned place preference/aversion. Rats/mice 
that have undergone injury or noxious insult, when placed in 
a two- chambered arena, will choose to spend more time in the 
chamber which has been paired previously with administra-
tion of an analgesic drug, likely due to positive affect/reward 
associated with the relief of ongoing pain (He et al., 2012). 
In other work, researchers have investigated rodent locomo-
tor activity in the home cage as compared to a novel envi-
ronment (e.g. an open field arena), or conditioned operant 
responding, and found that injury or noxious insult typically 
reduces or suppresses locomotor activity in a novel environ-
ment (pain- depressed behaviour) in a manner which can be 
reversed by analgesic drugs (Bree et al., 2015; Buvanendran 
et  al.,  2008; Martin et  al.,  2004). However, regarding the 
translational aspect, it is difficult to ascertain whether ani-
mals are less active because they are experiencing ongoing 
pain, or whether activity itself is evoking pain, with a conse-
quent avoidance- related reduction in activity. In addition, the 
analgesic drugs to which the above models have been shown 
to be sensitive are those often used as standard- of- care with 
varying degrees of success in the clinical setting (e.g. opioids, 
NSAIDs, local anaesthetics, alpha- 2- adrenoceptor agonists). 
The rat and mouse grimace scales represent another attempt 
to assess ongoing or spontaneous pain in rodents (Langford, 
Langford, et  al.,  2010; Sotocinal et  al.,  2011). They have 
been used mostly with models of acute or tonic pain, or short- 
term post- operative pain monitoring (in the context of animal 
welfare) but there is a relative paucity of evidence for their 
utility in animal models of chronic pain. Non- evoked rest-
ing pain in animals after surgical incision occurs immediately 
thereafter and might translate to pain at rest in patients after 
surgery (Segelcke et  al.,  2019). In vivo electrophysiology 
may also provide insight into the extent to which dorsal horn 
neuronal activity occurs in the absence of evoked stimulation 
of the peripheral receptive field. High levels of spontaneous 
activity are not evidenced by deep dorsal horn convergent 
neurons in osteoarthritic or spinal nerve ligated (SNL) male 
rats (Bee et al., 2011; Rahman et al., 2015). In contrast, con-
vergent neurons in the ventral posterior thalamus do exhibit 
substantially higher rates of spontaneous firing in SNL male 
rats compared to their sham- operated counterparts (Patel & 
Dickenson,  2016), which may relate to ongoing pain after 
nerve injury. These results likely represents an increased re-
ceptive field and primary afferent input to the dorsal horn that 
is reflected in increased ascending pathway activity and thus 
thalamic neuronal activation patterns. Contrasting findings 
demonstrate spontaneous activity in some dorsal horn neu-
rons after surgical incision, which could relate to non- evoked 
post- surgical resting pain in patients (Pogatzki et al., 2002; 
Xu et  al.,  2009). These dorsal horn neurons were different 
from those related to mechanical hypersensitivity (Pogatzki 
et al., 2002; Xu et al., 2009), but not fully characterized to 
allow comparison with prior findings in deep dorsal horn 
convergent neurons (Bee et al., 2011; Rahman et al., 2015).
3.3 | Considering sex and age
The overwhelming majority (approximately 80%) of pre-
clinical studies have been performed in young adult male 
rats or mice (Zucker & Beery,  2010). However, the clini-
cal reality is that males and females differ with respect to 
pain tolerance and thresholds, and chronic pain conditions 
have differing prevalence in females and males, with many 
being more prevalent in females (Bartley & Fillingim, 2013; 
Mogil,  2012; Pogatzki- Zahn et  al.,  2018). There has been 
increased recognition of this paradox in recent years, and 
many grant funding agencies now require the gender issue 
to be addressed satisfactorily. Furthermore, with an increas-
ingly ageing population worldwide, chronic pain disorders 
that affect the elderly should be modelled more commonly 
in aged rats and mice. Aged animals may be sometimes dif-
ficult to study because of size and comorbidities, but pro-
vide valuable information on age- related pathophysiology 
and pharmacology of pain (Jourdan et  al.,  2002; Pickering 
et al., 2006). Moreover, further research into pain in children 
and adolescents is required. But these areas also present their 
own challenges. Comparing both sexes has the potential to 
double animal numbers, aged rodents are significantly more 
expensive than young adult rodents and very young rodents 
require expensive and labour- intensive breeding programmes 
and can be technically challenging.
4 |  EXPLORING PAIN 
PERCEPTION AND ITS 
MODULATION IN HEALTHY 
HUMAN VOLUNTEERS
Exploring the neural mechanisms underlying the percep-
tion of pain and its modulation in healthy human volun-
teers requires methods to induce pain experimentally in a 
safe and controlled fashion. Obviously, many of the in vivo 
techniques that are used in non- human animal models are 
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not applicable to human volunteers. Despite the inherent 
limitations to human research, several methods have been 
developed to activate skin, muscle and visceral nocicep-
tors in humans, to induce peripheral and central sensitiza-
tion experimentally, and to characterize nociception along 
the entire human neuraxis. A promising perspective is the 
use of these methods in phase 1 clinical trials to determine 
target engagement, in addition to safety, tolerability and 
pharmacokinetics of a novel compound. The ability to de-
termine at a very early stage whether or not a significant 
effect on nociception can be observed below the maximum 
tolerable dose in healthy volunteers could reduce the fail-
ure rate of clinical trials.
4.1 | Experimental induction of pain in 
human volunteers
Exploring the neural mechanisms underlying the percep-
tion of pain and its modulation in healthy human volun-
teers requires methods to induce pain experimentally in 
a safe and controlled fashion. The most- often used tech-
niques to produce pain aim at activating nociceptors in-
nervating the skin. These include, (1) thermal stimulation 
of heat- or cold- sensitive skin nociceptors using radiant 
heat, contact heat or contact cold, (2) mechanical stimula-
tion of mechano- sensitive skin nociceptors, (3) chemical 
activation of nociceptors using substances that activate or 
sensitize nociceptors such as topical capsaicin, and (4) di-
rect electrical stimulation of nociceptive afferents (Arendt- 
Nielsen et  al.,  2007; Plaghki & Mouraux,  2005). These 
methods can also be used to generate nociceptive input in 
non- human animals, and (backward) translation could be 
improved by better alignment of the methods used. A first 
important point to consider when comparing the methods 
used to induce pain is selectivity. All the above- mentioned 
stimuli can activate nociceptive afferents and produce pain. 
However, many of these techniques unavoidably also ac-
tivate non- nociceptive somatosensory afferents. Lack of 
selectivity makes it challenging to determine whether the 
stimulus- evoked responses are produced by nociceptive 
or non- nociceptive somatic input and as such complicate 
elucidating which mechanisms are involved, for example, 
when observing drug- induced effects on these responses. 
Mechanical stimuli such as pinprick stimuli can activate no-
ciceptors, but will unavoidably also activate low- threshold 
mechanoreceptors (LTM). Similarly, because the electrical 
activation threshold of peripheral nerve fibres is inversely 
proportional to their diameter, electrical stimuli having 
the ability to activate unmyelinated or thinly- myelinated 
small- diameter nociceptive afferents almost unavoidably 
also activate non- nociceptive large- diameter afferents 
– except when special electrodes are used to selectively 
activate free nerve endings located in the most superficial 
layers of the skin (Inui et al., 2002; Mouraux et al., 2010). 
In contrast, thermal stimuli have the advantage of activat-
ing heat- sensitive free nerve endings without concomi-
tantly activating LTMs (Plaghki & Mouraux, 2005).
Even though most nociceptors are polymodal, differ-
ent types of nociceptive stimuli can preferentially activate 
different types of nociceptive afferents. Mechanical stim-
uli may be expected to preferentially activate mechano- 
sensitive nociceptors, heat stimuli to activate heat- sensitive 
nociceptors and cold stimuli to activate cold- sensitive af-
ferents. Moreover, some nociceptors are predominantly 
sensitive to phasic stimuli whereas other nociceptors re-
spond preferentially to long- lasting tonic stimuli (Meyer & 
Campbell, 1981; Treede et al., 1995). Thresholds may also 
vary (Churyukanov et  al.,  2012; Treede et  al.,  1995). As 
an example, intense short- lasting phasic heat stimuli such 
as those generated by a high power infrared laser pulse di-
rected onto the skin have been shown to generate responses 
almost exclusively related to the activation of one specific 
type of heat- sensitive afferent, so- called A- fibre Type 2 
nociceptors, with very little contribution of other types 
of heat- sensitive nociceptors such as Type 1 A- fibre noci-
ceptors and C- fibre nociceptors (Bromm & Treede, 1987). 
Because the respective contribution of these different types 
of nociceptive afferents to clinical pain remains largely 
unknown, this raises questions about the translatability to 
patients of results obtained using transient experimental 
stimuli in healthy volunteers. Furthermore, when sensitized 
for example by inflammation, the response properties of 
nociceptors may change. The afferents activated by a given 
nociceptive stimulus in physiological conditions could thus 
differ from those activated in pathological conditions such 
as inflammatory pain and neuropathic pain. In human skin, 
so- called ‘silent nociceptors’ account for almost a quar-
ter of nociceptors (Schmidt et  al.,  1995). Rodent studies 
have linked un- silencing of these nociceptors to hyperal-
gesia during inflammation and cancer- induced bone pain 
(Kucharczyk et al., 2020; Prato et al., 2017).
The above- mentioned stimulation techniques all activate 
exteroceptive nociceptors of the skin. Other stimulation 
techniques have been developed to explore interoceptive no-
ciception, i.e. the neural activity related to noxious stimuli 
occurring inside the body, such as those involved in muscu-
loskeletal pain and visceral pain. Because pain arising from 
muscles, ligaments and tendons, bones and the viscera are 
most common in pathological conditions, understanding 
interoceptive nociception has a high clinical relevance. 
However, the techniques to activate interoceptive nocicep-
tors are technically challenging to implement, difficult to 
control and often intrusive. Such as for skin nociceptors, 
electrical, mechanical, thermal and chemical stimuli can be 
used to activate muscle nociceptors and visceral nociceptors 
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(Arendt- Nielsen et al., 2007; Drewes et al., 2003; Graven- 
Nielsen,  2006; Staahl & Drewes,  2004). Intramuscular 
electrical stimulation using a needle electrode can selec-
tively activate sensory afferents of the stimulated muscle. 
Similarly, endoscopic probes can be used to activate noci-
ceptors innervating the walls of hollow organs. Such as for 
electrical stimulation of skin nociceptors, the main draw-
back of deep tissue electrical stimulation is that the elicited 
responses can be confounded by concurrent activation of 
non- nociceptive afferents and efferents (e.g. motor nerves). 
Mechanical stimuli can also be used, such as focused mus-
cular pressure using pressure algometry, pressure applied 
to the entire circumference of a limb using cuff algometry, 
and distension of hollow organs using balloons. However, 
mechanical stimulation of muscle nociceptors using ex-
ternal pressure applied against the skin unavoidably also 
activates skin mechanoreceptors, even though skin no-
ciceptors seem not to play a major role (Graven- Nielsen 
et  al.,  2004; Kosek et  al.,  1999). Furthermore, the actual 
pressure applied against the wall of a hollow organ using 
balloon distension is difficult to control – but new methods 
have been developed to better estimate stimulus- evoked 
tissue strains (Drewes, Gregersen, et al., 2003). One study 
has used thermal stimulation of muscle nociceptors by in-
jection of warm or cold isotonic saline (Graven- Nielsen 
et  al.,  2002), and a few studies have used thermal stimu-
lation of visceral nociceptors with temperature- controlled 
balloons, with the advantage of selectivity for thermosen-
sitive afferents (Villanova et al., 1997). Finally, intramus-
cular injections of pro- nociceptive substances or their local 
delivery in hollow organs using endoscopic probes have 
been used extensively to induce experimental muscle pain 
and visceral pain in humans, such as hypertonic saline, 
acid and capsaicin (Arendt- Nielsen et  al.,  2007; Drewes, 
Gregersen, et  al.,  2003; Graven- Nielsen,  2006; Staahl & 
Drewes,  2004). Endogenous algesic substances can also 
be used to induce muscle pain, such as the induction of 
muscular ischemia by contractions during occluded blood 
flow (Graven- Nielsen et al., 2003; Issberner et al., 1996), 
or the induction of muscle soreness by unaccustomed mus-
cular exercise (Newham et  al.,  1983; Slater et  al.,  2003). 
Key characteristics of experimental musculoskeletal pain is 
their diffuse nature compared to a very localized skin pain 
and importantly pain referral to other structures not being 
stimulated.
4.2 | Experimental induction of 
peripheral sensitization and facilitation of 
central mechanisms
In patients, pain is most often a consequence of tissue lesion 
and inflammation, which induce peripheral sensitization, i.e. 
increased sensitivity of peripheral nociceptors. It is increas-
ingly acknowledged that sustained peripheral nociceptive 
input even without peripheral sensitization tends to enhance 
the responsiveness of the central nervous system to that pe-
ripheral nociceptive input, such as the phenomenon of cen-
tral sensitization at the level of the spinal cord that has been 
studied extensively in rodent models of pain. However, cen-
tral sensitization can occur in the absence of a peripheral in-
sult. These changes can dramatically modify the function of 
the nociceptive system and could explain pain symptoms in 
many patients. To induce peripheral and central sensitization 
in human volunteers, several approaches have been devel-
oped (Binder,  2016). These include experimental lesions of 
the skin such as burn and freeze lesions (Martin et al., 2019), 
UVB- induced tissue damage and inflammation, topical appli-
cation or intradermal injection of nociceptive or inflammatory 
substances such as capsaicin, menthol, cinnamaldehyde and 
nerve growth factor (NGF), high- frequency electrical stimula-
tion of the skin (Klein et al., 2005; Vollert et al., 2018) and an 
experimental incision in the skin of human volunteers (Fißmer 
et al., 2011; Pogatzki- Zahn et al., 2010, 2019b). Some of these 
approaches have also been used to induce sensitization in 
muscle tissues or hollow viscera (e.g. repeated intramuscu-
lar infusions of nociceptive substances (Hayashi et al., 2013), 
high- frequency electrical stimulation of muscular and fascia 
afferents (Schilder et  al.,  2016), capsaicin infusions in the 
gastro- intestinal tract (Drewes, Schipper, et al., 2003).
The commonality of all these experimental techniques 
is that they all induce some amount of hyperalgesia. All but 
high- frequency electrical stimulation of nociceptive afferents 
markedly sensitize transduction by peripheral nociceptors, 
either via a direct action on the molecular receptors responsi-
ble for this transduction (e.g. agonists of TRP channels such 
as capsaicin, menthol and cinnamaldehyde), or by producing 
local inflammation which in turn sensitizes the nociceptors 
(e.g. tissue lesions producing tissue inflammation). Notably, 
any sustained experimental activation of peripheral nocicep-
tors will also produce some amount of tissue inflammation, 
because of the local release of neuropeptides by peptider-
gic nociceptors, and this explains why topical capsaicin or 
high- frequency electrical stimulation of the skin can produce 
a cutaneous flare. Furthermore, any sustained activation of 
peripheral nociceptors is likely to induce some amount of 
central sensitization, hallmarked by the development of sec-
ondary mechanical hyperalgesia, i.e. an increased sensitivity 
to noxious mechanical stimuli that extends beyond the zone 
of injury or inflammation. This is most evident with high- 
frequency electrical stimulation of the skin although leav-
ing the stimulation site less affected. In healthy volunteers, 
five seconds of high- frequency electrical stimulation using 
an electrode designed to preferentially activate nociceptive 
free nerve endings induces an increase in sensitivity to me-
chanical pinprick stimuli that lasts several hours and extends 
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well beyond the stimulated skin (Klein et al., 2004). A simi-
lar time course of pinprick hyperalgesia can be produced by 
an experimental surgical incision that is, however, accompa-
nied by transient spontaneous pain and hyperalgesia to heat 
(Fißmer et al., 2011; Pfau et al., 2011). Following prolonged 
stimulation of muscle nociceptors, deep- tissue hyperalgesia 
is sometimes accompanied with widespread hyperalgesia and 
facilitation of central pain mechanisms (e.g. temporal summa-
tion of pain and expanded pain referral) (Andersen et al., 2008; 
Doménech- García et al., 2016; Hayashi et al., 2013).
Interestingly, these experimental pain models in human 
volunteers have also often been used in animal models of 
pain, thereby making it possible to establish links between 
pathophysiological observations that are possible only in 
non- human animals – such as the recording of spinal neurons 
or the immunohistochemical assessment of glial activation in 
the dorsal horn – and behavioural observations that are possi-
ble only in humans such as assessing self- reported changes in 
pain perception (Pogatzki- Zahn et al., 2017).
Several authors have referred to some of the above- 
mentioned methods as “surrogate models of neuropathic pain” 
(Klein et al., 2005). Although peripheral sensitization and fa-
cilitated central mechanisms may contribute to the positive 
symptoms of neuropathic pain, there are arguments against 
this because neuropathic pain obligatorily involves a lesion 
or disease of the somatosensory system, and none of these 
models reproduce any such lesion or disease. Furthermore, 
all these methods consistently produce some amount of hy-
peralgesia, but generate little or no static or dynamic tactile 
allodynia and cold allodynia, although these symptoms are 
highly prevalent and most disabling in many neuropathic pain 
conditions. For obvious ethical reasons, there are thus cur-
rently no experimental models of neuropathic pain in human 
volunteers. One exception could have been the prolonged 
and/or high- concentration treatment of the skin with capsa-
icin, as it induces a selective nociceptor denervation of the 
epidermis (Nolano et al., 1999). However, although this in-
tervention reproduces the negative symptoms of neuropathic 
pain (i.e. a reduced sensitivity to nociceptive stimuli lasting 
several days), the capsaicin- induced denervation does not 
reproduce the positive symptoms such as spontaneous pain, 
allodynia and hyperalgesia. Another exception could be the 
thermal grill illusion, in which interlaced warm and cool tem-
peratures applied against the skin may produce a paradoxical 
unpleasant sensation mimicking some of the positive symp-
toms of neuropathic pain (Craig & Bushnell, 1994).
4.3 | Experimental manipulation of 
descending modulatory pathways
The discovery in rats that spinal neurons relaying nociceptive 
input can be inhibited by nociceptive input applied outside 
their own segmental receptive field – a phenomenon referred 
to as diffuse noxious inhibitory controls (DNIC) and involv-
ing a spinal- bulbar- spinal loop (Le Bars et al., 1979a, 1979b) 
– prompted extensive research in humans on the involve-
ment of DNIC in the modulation of pain. In human volun-
teers, the phenomenon is typically studied by characterizing 
the effect of a remote or heterotopic noxious conditioning 
stimulus (HNCS) on the responses to a second painful test 
stimulus – so- called conditioned pain modulation (CPM) 
(Pud et al., 2009). Most often, HNCS is achieved by immers-
ing an upper limb extremity in noxious cold or hot water, 
and the outcome measure is the reduction in pain ratings to 
brief noxious test stimuli applied to another region of the 
body, such as the contralateral lower limb, during the ap-
plication of HNCS. Other modalities for HNCS have been 
extensively used in experimental and clinical studies, such 
as cuff pressure stimulation (Cummins et al., 2020; Graven- 
Nielsen et al., 2017). Animal studies have also shown that the 
inhibitory effect of HNCS on spinal neurons persists some 
minutes after the termination of HNCS. For this reason, other 
studies have assessed in humans the changes in sensitiv-
ity to the test stimulus not only during but also after HNCS 
(Willer et  al.,  1989). Although unequivocal evidence that 
malfunctioning descending controls may be a primary driver 
of any chronic pain condition is lacking, it is noteworthy that 
dysregulation of DNIC is observed in several rodent mod-
els of chronic pain (Bannister et al., 2015, 2017; Lockwood 
et  al.,  2019), and that the effects of CPM can be lower in 
patients with chronic pain as compared to controls (Jennings 
et al., 2014; Lewis et al., 2012; McPhee et al., 2020; Petersen 
et al., 2019; Potvin & Marchand, 2016; Yarnitsky, 2010). One 
hint that descending modulation is involved in the severity of 
pain conditions comes from studies showing that CPM is pre-
dictive of the development of post- surgical acute and chronic 
pain (Ruscheweyh et  al.,  2017; Yarnitsky et  al.,  2008). 
Underlying noradrenergic mechanisms could explain, in pa-
tients with chronic pain, the relationship between reduced 
CPM and the beneficial effects of tapentadol (μ- opioid re-
ceptor agonist and noradrenaline reuptake inhibitor, NRI) 
and duloxetine (serotonin norepinephrine reuptake inhibitor, 
SNRI) (Niesters et  al.,  2014; Yarnitsky et  al.,  2012). This 
back- translates since NRIs reinstate the functional expres-
sion of DNIC in rat models of neuropathic pain (Bannister 
et  al.,  2015). Even so, whether the pain reduction induced 
during and/or after HNCS in humans can be attributed in full 
or in part to a modulation of nociception at spinal level, and 
whether this modulation results from an engagement of DNIC 
remain open questions. When one relies on pain perception, 
higher- order cognitive processes such as HNCS- induced 
distraction from the test stimulus are likely to contribute to 
the observed effects. The finding that the spinal nociceptive 
withdrawal reflex (NWR) can be depressed by HNCS sug-
gests that HNCS can modulate nociception at spinal level in 
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humans (Jure et al., 2019; Willer et al., 1989). Furthermore, 
studies in rodents have shown that the functional expression 
of DNIC is influenced by subcortical brain regions associated 
with emotional processing (Phelps et  al.,  2019), indicating 
that cognitive and affective factors may modulate the experi-
ence of pain by modulating this mechanism.
Beyond DNIC, the NWR can also be modulated directly 
by cognition and affect. An increasing number of studies ex-
plore how these factors may modulate pain through an ef-
fect on the descending pathways that can inhibit or facilitate 
spinal nociception (Tracey & Mantyh, 2007). This is exem-
plified by recent studies exploring how induction of placebo 
or nocebo effects may modulate nociception – and, thereby, 
pain perception – using functional neuroimaging techniques 
to identify placebo/nocebo- related changes in activity at 
brain, brainstem and spinal levels (Geuter & Büchel, 2013), 
as well as pharmacological manipulations to understand the 
role of different neurotransmitter systems such as descending 
opioidergic pathways (Eippert, Bingel, et al., 2009).
Part of the effects of psychological factors on pain perception 
may thus involve descending mechanisms controlling nocicep-
tion at spinal level. However, supraspinal effects are probably 
equally important, and changes in the function of peripheral 
nociceptors might also occur. For example, the phenomena of 
stress- induced analgesia and stress- induced hyperalgesia have 
been shown to involve multiple mechanisms that modulate both 
spinal (via descending pain pathways) and supraspinal compo-
nents of the pain pathways, and stress- induced responses may 
also impact nociception in the periphery (Burke et al., 2017; 
Butler & Finn, 2009; Jennings et al., 2014).
4.4 | What can be recorded in humans?
As compared to studies conducted in animals, studies in 
human volunteers offer the advantage that the results may 
be more closely related to what is observed in patients be-
cause there will be no inter- species difference, and because it 
is possible to obtain self- reports of pain intensity or unpleas-
antness. Furthermore, in patients, questionnaires can be used 
to assess how pain impacts mood, daily life activities and 
quality of life. On the other hand, human research is limited 
by the techniques that are available to sample neural activ-
ity (and proxies of this) and, even more so, the techniques 
that can be used to induce and characterize pain- related 
changes in function or structure of the nervous system that 
may occur in patients exposed to various pathologies such 
as tissue lesions and inflammation, and lesions of the nerv-
ous system. Nevertheless, several techniques allow sampling 
nociception- related activity at all levels of the human neu-
raxis and examples are given below.
At the peripheral level, microneurography is a minimally 
invasive technique to measure action potentials of single 
(C- fibre) nociceptors or sets of nociceptors (Ackerley & 
Watkins,  2018; Serra,  2009). Also at the peripheral level, 
electrophysiological and psychophysical sensory “threshold 
tracking techniques” have been developed to assess the excit-
ability of large- diameter sensory axons and gain insight into 
ion channel activity using a combination of transcutaneous 
conditioning and test electrical pulses, and attempts have 
been made to extend these techniques to the assessment of 
small- diameter nociceptive afferents (Bostock et  al.,  1998; 
Hugosdottir et al., 2019; Kiernan et al., 2020).
To assess nociception at spinal level, the NWR has been 
used extensively (Neziri et al., 2010; Sandrini et al., 2005). 
Most- often, it is elicited by noxious stimulation of the lower 
limb (e.g. transcutaneous electrical stimulation of the sural 
nerve at the lateral malleolus or electrical stimulation of the 
foot sole) and recorded from a flexor muscle of that same 
lower limb. Although this reflex is not a direct measure of the 
activity of spinal neurons relaying nociceptive input to the 
brain, and while isolating this nociceptive reflex from reflex 
activity triggered by non- nociceptive large- diameter afferents 
can be tricky, the threshold and amplitude of the NWR can 
be expected to relate to the responsiveness of spinal neurons 
responding to nociceptive input. The reflex receptive fields 
from where the NWR can be elicited (e.g. on the foot) is 
an additional measure (Andersen et al., 2001) where objec-
tive quantification of the area have demonstrated enlarge-
ment in clinical conditions (Biurrun Manresa et  al.,  2013). 
Complementary to the NWR, and since the technique re-
mains very challenging, several research centres are now able 
to sample nociception- related activity at spinal level using 
BOLD- fMRI (Powers et al., 2018).
At brainstem level, the blink reflex is a trigemino- facial 
reflex aimed at triggering eyelid closure in response to a 
threatening stimulus (Cruccu et  al.,  2005). It can be easily 
measured by stimulating skin innervated by the supraorbital 
nerve and sampling the elicited response from the orbicularis 
oculi muscle. The R2 component of this reflex is mediated 
by A- beta and A- delta fibres, which synapse with wide dy-
namic range neurons in the medulla. Autonomic and arousal 
responses such as variations in skin conductance, pupil di-
ameter and heart rate can also be used to assess involvement 
of the brainstem and hypothalamus. Using high- resolution 
fMRI, it is now also possible to measure BOLD activity re-
lated to nociception and its modulation in subcortical and 
brainstem structures, including the periaqueductal grey 
(PAG) and rostral ventromedial medulla (RVM) which are 
thought to play a critical role in descending pain modulation 
(Bingel & Tracey, 2008).
Finally, at the level of the cortex, nociception- evoked 
neural activity can be readily assessed using non- invasive 
scalp electroencephalography (EEG) and magnetoenceph-
alography (MEG) (Mouraux, 2019). The recorded signals 
constitute a direct but macroscopic or population- level 
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measure of synchronized electrocortical activity. This in-
cludes the recording of evoked brain potentials elicited by 
brief nociceptive stimuli such as laser- evoked brain poten-
tials, pinprick- evoked brain potentials (Iannetti et al., 2013) 
and some more recent approaches attempting to isolate cor-
tical activity related to sustained noxious input such as time- 
frequency analyses to measure tonic variations in ongoing 
oscillatory activity (reviewed by Ploner et al. (2017)) and 
the recording of nociceptive steady- state responses (Colon 
et al., 2017). Using depth electrodes or subdural electrode 
grids implanted for the presurgical evaluation of epilepsy 
(intracerebral EEG or electrocorticography), several cen-
tres have also measured directly nociception- evoked neural 
activity from various brain structures such as the operculo- 
insular cortex (Frot et  al.,  2007). Interestingly, studies in 
animals have suggested that experimental modulation of 
some of these responses may modulate pain behaviour. 
For example, Tan et  al.  (2019) showed that stimulus- 
evoked gamma- band oscillations in the somatosensory 
cortex which have also been observed in humans (Gross 
et al., 2007) are enhanced in mice with inflammatory pain, 
and that optogenic induction of similar oscillations induces 
behaviours suggestive of pain, allodynia or paraesthesia.
Functional neuroimaging techniques that measure local 
variations in cerebral blood flow or oxygenation due to 
neurovascular coupling and the hemodynamic response 
have also been used extensively (Tracey & Mantyh, 2007): 
BOLD fMRI, but also magnetic resonance arterial spin la-
belling (ASL), positron emission tomography (PET), and 
functional near- infrared spectroscopy (fNIRS). The high 
spatial resolution provided by these techniques to sample 
brain activity, as well as the ability to of these techniques 
to characterize activity from deep brain structures, has pro-
vided an unprecedented view of how the brain responds to 
painful stimuli, but also how the brain may modulate pain 
perception including through the activation of descend-
ing modulatory pathways although it is not yet possible 
to clearly study brainstem to dorsal horn pathways using 
fMRI.
4.5 | From healthy volunteers to patients
Observations made in healthy volunteers – including sev-
eral observations that tend to replicate observations made in 
animal models of pain such as the induction of secondary 
hyperalgesia by high- frequency electrical stimulation of no-
ciceptive afferents, cold injury, an experimental incision or 
capsaicin (Fißmer et  al.,  2011; Klein et  al.,  2005; Madden 
et al., 2019), and the inhibitory effects of CPM have contrib-
uted to a better understanding of the mechanisms underlying 
pain perception and its modulation. A driving motivation for 
this research is that it could also lead to a better understanding 
of the mechanisms underlying the pain experienced by pa-
tients and, thereby, to new diagnostic and therapeutic ap-
proaches. However, translating findings in healthy volunteers 
to what occurs in patients is an ongoing challenge.
The mechanisms underlying short- lasting experimental 
pain in healthy human volunteers could be quite different 
from the mechanisms underlying the pain experienced by pa-
tients during days, weeks, months or even years (Figure 2). 
Similarly, the mechanisms at play in experimental models of 
inflammation, sensitization of peripheral and central mech-
anisms induced by experimental procedures that induce spa-
tially restricted changes in pain sensitivity lasting minutes 
to hours could be very different from the mechanisms that 
are at play in patients suffering from chronic nociceptive, 
inflammatory or neuropathic pain. In other words, gener-
alization may be limited to the process from acute to pro-
longed pain but less appropriate to generalize from healthy 
volunteers to patients. Several studies have suggested a mis-
match between the brain regions that are typically activated 
by acute experimental pain and those that are most active in 
patients suffering from clinical pain such as low back pain 
(Baliki et al., 2006; Wasan et al., 2011) or pain following a 
surgical tooth extraction (Hodkinson et  al.,  2013; Howard 
et al., 2011). On a positive note, characterizing and under-
standing these differences could be a way to understand the 
changes in structure and function of the nervous system 
that underlie the chronification of pain. Interestingly, there 
are also examples of manifestations that are comparable to 
what is observed in patients. Recently several attempts have 
successfully studied prolonged experimental pain models in 
otherwise healthy subjects by following the cortical neuro-
plastic manifestations in the course of pain for several days 
(De Martino et al., 2018; De Martino et al., 2018, De Martino 
2019; Schabrun et al., 2016). Another very important issue is 
the discussion of causality when interpreting differences ob-
served in patients with pain as compared to controls. Except 
in the case of post- surgical pain, the lack of pre- pain mea-
surements makes it often impossible to determine whether a 
particular finding is causal or consequential to the presence 
of ongoing pain for a long time, or whether it constitutes a 
pre- existing trait present in these patients. Furthermore, it is 
often difficult to disentangle whether observed differences 
reflect an unspecific change in state associated to the con-
dition. Here, large cohort studies or the relative rare patient 
conditions where baseline recordings can be obtained may 
be useful, as well as prolonged experimental pain studies 
where baseline recordings are included. Recurrent pain con-
ditions may also be useful to understand the pain systems 
with and without ongoing pain, e.g. in recurrent low back 
pain patients where measures related to pro- nociceptive 
mechanisms (temporal summation of pain) were enhanced 
only during ongoing clinical pain, while measures related 
to anti- nociceptive mechanisms (CPM) seem depressed both 
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in periods with pain and periods without pain (McPhee & 
Graven- Nielsen, 2019).
4.6 | Considering sex and age
Epidemiological studies as well as clinical studies have 
shown that women are at greater risk for many pain condi-
tions (Mogil, 2012). Except for studies involving administra-
tion of a drug, the majority of studies conducted in healthy 
human volunteers recruit both men and women, and sev-
eral studies have explored sex- related differences specifi-
cally. Differences in the responses to experimental pain and 
its modulation in male and female have been reported, but 
these appear to be somewhat marginal as compared to the 
differences observed in patients. This is in line with the no-
tion that chronic pain is not necessarily related to changes in 
the responses to experimental pain, and indicates that further 
research is needed.
Although the prevalence of chronic pain greatly increases 
with age, and is a main determinant of disability in the el-
derly (Gibson, 2007), the majority of studies on pain percep-
tion and its modulation conducted in human volunteers are 
biased towards younger individuals. Studies conducted in 
aged healthy volunteers indicate reduced sensitivity to exper-
imental nociceptive stimuli (Chakour et al., 1996; Pickering 
et al., 2002, 2014), which could be explained, at least in part, 
to an age- related reduction of nociceptor innervation density 
(Besné et al., 2002), but also tendency for reduced pain tol-
erance which might result from age- related differences in the 
mechanisms modulating pain perception, as well as changes 
in cognitive function (Defrin et al., 2015).
5 |  TRANSLATING 
EXPERIMENTAL TECHNIQUES 
TO STUDY PAIN INTO CLINICAL 
TOOLS
5.1 | Tools for measuring pain in patients
Some researchers have put forward the idea that pain- related 
brain activity sampled using functional neuroimaging could 
be used as objective measures of pain perception. A crucial 
point to consider here is that pain, like any other percept, is 
an intrinsically subjective experience. Therefore, even if the 
measure itself is objective – like an objective change in re-
gional cerebral blood flow – measures of pain derived from 
functional neuroimaging will be relevant if and only if they 
account for the subjectivity of the pain experience. Another 
point to consider is generalizability. For example, a marker 
for pain derived from brain activity sampled in healthy vol-
unteers exposed to acute experimental pain might be efficient 
at identifying and quantifying this acute experimental pain, 
but have limited abilities to identify and quantify pain in 
clinical conditions. Pain assessment in persons who cannot 
communicate is done with observational scales providing 
only some degree of detection and possible presence of pain 
(Pickering et al., 2018). Recently, brain imaging in pain con-
ditions was thoroughly reviewed and it was concluded that it 
is not possible to use it for supporting or disputing a claim of 
chronic pain but rather imaging is justified for studies of pain 
mechanisms (Davis et al., 2017).
5.2 | Tools for mechanism- based 
diagnosis of pain in clinical conditions
Researchers have also suggested that the different neuro-
imaging techniques used to explore pain perception in hu-
mans could be used to characterize the engagement of the 
different mechanisms or systems that can modulate the pain 
experience, such as the top- down influence of nociceptive 
transmission at the level of the spinal cord, the changes in re-
sponsiveness due to central sensitization, and the modulation 
of pain by placebo, nocebo, cognitive control, emotions and 
attention (Bingel & Tracey,  2008). Similarly, neuropathic 
pain – i.e. pain caused by a lesion or disease of the soma-
tosensory nervous system – is thought to involve specific 
mechanisms leading to specific changes in nociceptive func-
tion. The above- mentioned techniques can be used to dem-
onstrate the existence of a lesion affecting the nociceptive 
system. Furthermore, techniques such as microneurography 
can be used to characterize abnormal excitability of periph-
eral afferents in patients with peripheral neuropathic pain.
Altogether, this could open the prospect of stratifying 
patients in mechanistically distinct groups, of predicting 
response to treatment, and of proposing tailored treatments 
most likely to provide pain relief (Baron et al., 2017). A few 
studies have followed this line in predicting treatment re-
sponse to drugs and generated encouraging results (Harris 
et al., 2013; Yarnitsky et al., 2012), including the ability to 
predict placebo responses (Vachon- Presseau et  al.,  2018). 
These promising results have wide clinical implications in 
terms of patient stratification and design of future clinical 
trials: failures of a treatment may be due to the fact that it is 
given to the wrong patients, or at a wrong moment in time 
relative to disease progression.
5.3 | Tools for improving future 
clinical trials
Several studies have shown that the methods described 
above can be used to characterize drug- induced modulation 
of nociception in healthy human volunteers. Among many 
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examples, in patients with neuropathy, peripheral nerve ex-
citability testing is sensitive to the suppression of abnormal 
sodium currents induced by mexiletine (Isose et al., 2010). 
Similarly, at the level of the spinal cord, several studies have 
demonstrated drug- induced effects on the NWR (Sandrini 
et al., 2005). Also in healthy volunteers, Truini et al. (2010) 
showed that laser- evoked brain potentials are significantly 
affected by a single administration of tramadol compared 
to placebo, and it has been shown that the BOLD- fMRI re-
sponses to mechanical pinprick stimuli delivered to skin sen-
sitized by capsaicin can be suppressed by known analgesics 
including opioids and gabapentinoids (Wanigasekera et al., 
2016, 2018; Wise et al., 2002).
A critical step in clinical drug studies is to determine 
whether the candidate drug achieves target engagement 
and at which dose. If feasible, this should be done already 
during Phase 1 studies in healthy subjects, i.e. before full 
clinical development. The fact that several measures of no-
ciception can readily be modulated by the administration of 
known analgesics in healthy volunteers suggests that this 
might be possible, and measures of drug- induced effects on 
nociception and its modulation in healthy volunteers could 
be used as a means to improve the odds of drug develop-
ment success (Davis et al., 2020). Stratification of patients 
with peripheral neuropathies in clinical trials using quan-
titative sensory testing (QST, based on studies like Baron 
et al.  (2017) and Vollert et al.  (2018)) or specific screen-
ing questionnaires aiming, for example, to identify patients 
with symptoms of neuropathic pain (Attal et  al.,  2018) 
has been encouraged already by the European Medicines 
Agency in its new guideline as a step towards increasing 
response rates in clinical trials by a mechanism- based 
treatment approach (European Medicines Agency, 2016). 
Furthermore, the markers of nociception that are sensitive 
to drug- induced effects in human volunteers could be back- 
translated into relevant preclinical models.
5.4 | Non- pharmacological 
neuromodulation of the nociceptive system
The observations in animals that stimulation of a given 
neuronal structure may inhibit selectively transmission of 
nociceptive input in the central nervous system and sup-
press pain behaviour has also translated into several non- 
pharmacological neuromodulation techniques aiming at 
reducing pain in patients by acting directly on the mecha-
nisms involved in its modulation. For example, thousands of 
patients are currently implanted each year with spinal cord 
stimulators, a technique that was initially justified by the con-
cept of the “gate control” theory of pain and the observation 
in animals that electrical stimulation of the dorsal columns 
inhibits nociceptive transmission at the level of the spinal 
cord. Yet, the actual mechanism of action of spinal cord stim-
ulation and other neuromodulation techniques such as motor 
cortex stimulation remains largely unknown. A better under-
standing of the effects of neuromodulation therapies could 
benefit from further back- translation to preclinical models.
6 |  INTERACTION BETWEEN 
SOMATOSENSORY AND 
PSYCHOLOGICAL SYSTEMS
Translational pain research is not only challenged by the 
forward and backward translation between different species 
and from health and disease states, but also by bi- directional, 
multifaceted influences between somatosensory and psy-
chological systems. Results from psychobiological research, 
targeting such bi- directional influences, have highlighted 
the impact of psychobiological mechanisms in the develop-
ment, maintenance, and therapy of chronic pain (Edwards 
et al., 2016; Meints & Edwards, 2018).
The effect of psychological processes on somatosensory 
processing, in particular pain processing, is well- described 
in human research. For example, expectations (including ex-
pectations induced by placebo or nocebo), perceived threat, 
catastrophizing, stress, self- efficacy, to name just a few ex-
amples, have been shown to strongly affect pain perception 
in acute as well as chronic pain states (Atlas & Wager, 2012; 
Butler & Finn,  2009; Elman & Borsook,  2018; Jennings 
et al., 2014; Meints & Edwards, 2018). All these factors can 
inhibit and facilitate nociceptive signalling at all levels of the 
neuraxis (Bräscher et al., 2016; Bushnell et al., 2013; Eippert 
et  al.,  2009; Galambos et  al.,  2019; Terry et  al.,  2016). In 
the context of placebo/nocebo research, it has been shown 
that effects of expectations can even outperform and override 
the effects of short- acting, highly potent opioidergic drugs 
(Bingel et al., 2011). In addition, the effects of psychologi-
cal processes on somatosensory processing have also been 
highlighted with respect to clinical pain. For example, such 
effects have been well- described in the context of visceral 
pain in functional gastrointestinal disorders (e.g. Elsenbruch 
et al., 2010; Icenhour et al., 2019), tellingly also termed dis-
orders of brain- gut interactions (Mayer et al., 2019).
However, while there is extensive work on psychobiolog-
ical mechanisms in humans, animal work is limited. This is 
not surprising, as many psychological processes are hard to 
assess in animals. Nevertheless, studies have demonstrated 
impressively similar effects in laboratory animal research 
compared to human work. For example, positive social in-
teractions decrease pain behaviour and nociceptive signalling 
in mice (Langford, Tuttle, et al., 2010), mild threat induced 
by the presence of stranger male mice induces hyperalgesia 
in male mice, while severe threat induces analgesia (Butler 
& Finn, 2009; Jennings et al., 2014; Langford et al., 2011), 
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and placebo analgesia has also been demonstrated in rodents 
(Nolan et al., 2012; Xu et al., 2018). Converging insights of 
human and animal research have been found recently on the 
interaction of cognition and chronic pain. Chronic pain has 
often been shown to be accompanied by impaired cognition 
(e.g. Rouch et al., 2020; Samartin- Veiga et al., 2019), for re-
view: Moriarty et al. (2011). Importantly, based on the results 
from basic science, a causal role of pain on impaired cog-
nition can be assumed and possibly underlying mechanisms 
delineated (Shiers et al., 2018, 2020; Xiong et al., 2020), indi-
cating a high potential for successful translational science in 
the context of psychobiological mechanisms. Nevertheless, 
one limiting factor in animal research is that the effect of psy-
chological factors has always to be inferred from behaviour, 
necessitating several assumptions on the psychological ef-
fects of experimental manipulations and for interpretation of 
the displayed behaviour.
Not only do psychological systems affect somatosensory 
signalling, but the somatosensory system can also modulate 
psychological processes. One well- known example is the ef-
fect of disturbed sleep on the perception on pain. While dis-
rupted sleep leads to an increased sensitivity to experimental 
pain (Seminowicz et al., 2019; Staffe et al., 2019), disturbed 
pain can also predict the development and maintenance of 
persistent pain (Finan et al., 2013; Nitter et al., 2012, for re-
view). In general, the embodiment framework assumes in-
fluences of our body on cognition, emotion, and behaviour 
as well as sensory and motor systems (Glenberg, 2010). Pain 
has been described as “inescapably embodied and embed-
ded” (Tabor et al., 2017), shifting the concept of pain from a 
passive, sensory experience to an active, motor experience. In 
a broader context, situational feelings have been described as 
being engrained by “somatic markers” in our bodies, thereby 
forming future actions (Bechara et al., 2000). Furthermore, 
the high comorbidity of chronic pain with affective disor-
ders, with some evidence pointing at a possible causal role of 
pain in the development of these affective disorders (Humo 
et al., 2019), suggests that the experience of pain can mod-
ulate mental well- being probably through shared underlying 
mechanisms (Becker et al., 2018; Borsook et al., 2016; Burke 
et al., 2015; Fitzgibbon et al., 2016).
In translational research, interactions of psychological 
and somatosensory systems are often neglected (Mao, 2012). 
However, considering the impact of psychological factors in 
the development, maintenance and therapy of chronic pain in 
humans, it appears essential to take such interactions into ac-
count in translational research, in particular to foster a better 
prediction from preclinical trials. In line with this reasoning, 
it has been shown that factors such as environmental enrich-
ment reduce pain sensitivity and pain behaviour in rodents 
(e.g. Gabriel et  al.,  2010; Wang et  al.,  2019), but a direct 
translation of these results to societal aspects on pain in hu-
mans is lacking so far (Bushnell et al., 2015). Nevertheless, 
an important step towards integrating psychological as-
pects in animal research has been taken by basic science 
focusing more and more on pain aversiveness and emotional- 
motivational pain responses, utilizing, for example, grimac-
ing, operant behaviour, and conditioned place preference in 
rodents (Gomtsian et al., 2018; Leitl & Negus, 2016; Tappe- 
Theodor et al., 2019; Tuttle et al., 2018). However, it remains 
open how such proxies relate to emotional- motivational pain 
experiences in humans. It appears an insolvable task to incor-
porate all known psychological factors from human research 
in animal research. Identifying central psychological factors 
and finding appropriate proxies in animals is one challenge 
in backward translation, which has received surprisingly little 
attention so far.
Focusing on psychological systems and backward transla-
tion, one could carry the question to extremes, asking whether 
we need backward translation to basic science for psychologi-
cal pain treatments. While this would allow, as outlined above, 
urgently needed investigations into fine- grained neurobiological 
mechanisms, impossible to investigate in humans, a proper im-
plementation in animal research appears inconceivable. In con-
trast, human pain research, in particular on primary pain, has 
strongly focused on psychological mechanisms, in part almost 
neglecting the knowledge on nociceptive mechanisms gained 
from basic research, and devaluating the role of nociception in 
chronic pain (Schweinhardt, 2019). Despite the fact that psycho-
logical factors can modulate pain perception, ascending nocicep-
tive input (evoked or spontaneous) can be assumed to be present 
in almost all pain patients. A large proportion of patients with 
chronic pain do not report restrictions in activity or participation 
(Pitcher et al., 2019), suggesting that psychological factors do not 
play a predominant role in these patients, while nociceptive pro-
cessing might have been underestimated (Schweinhardt, 2019). 
In this context, human research could be fostered by forward 
translation utilizing the knowledge from animal research to un-
derstand pain mechanisms in humans, particularly in incorpo-
rating and balancing the interaction between somatosensory and 
psychological mechanisms. Furthermore, backward translation 
could enrich animal research, for example, by mechanistic in-
vestigations using methods such as optogenetics or intracerebral 
drug injections in specific brain regions identified as important 
in human pain processing using brain imaging and incorporat-
ing somatosensory and psychological interactions. To solve the 
raised issues on interactions of somatosensory and psycholog-
ical systems in the context of translational research, interdisci-
plinary work is essential.
7 |  MAIN CHALLENGES IN 
PREVENTION OF PAIN
Translational approaches in pain research are important not 
only to treat but also to prevent pain from becoming chronic 
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or getting worse by causing secondary effects beyond pain, 
termed tertiary prevention. Currently, primary prevention of 
pain focuses on exercise and workouts in general and in those 
experiencing an acute pain episode (secondary prevention) like 
low back pain (Geneen et al., 2017). Clinical risk factors have 
been established in patients for early identification of patients at 
major risk for musculoskeletal chronic pain which are summa-
rized for easy use by red (biological) and yellow (psychosocial) 
“flags” as a most common construct, and added by blue (oc-
cupational), black (compensation) and white (socio- cultural) 
flags (Meyer et al., 2018) (see also https://www.iasp- pain.org/
Globa lYear). Most of the evidence behind these clinical risk 
factors and approaches to prevent pain from becoming chronic 
come from clinical investigations.
Screening for subgroups of patients regarding their risk 
for chronification is possible and might help to identify those 
patients with specific need for prevention (Hill et al., 2010). 
A similar approach has been taken for postoperative pain 
that, under certain circumstances, becomes persistent 
(Lavand’homme et al., 2018). Here, risk factors are indicated 
but not yet finally determined (Yang et al., 2019). There is 
however one important missing link for preventive approaches 
that in fact relates to translational aspects. To investigate pre-
ventive approaches related to the underlying biological mech-
anisms, animal studies are still required in order to investigate 
new and specific targets. However, the back translation to an-
imals and healthy human volunteers is hindered here by the 
fact that most available preclinical models lack translatabil-
ity. For example, approximately 10% of patients after surgery 
develop chronic pain and up to 40% after some specific surgi-
cal procedures like thoracotomy and breast surgery (Fletcher 
et  al.,  2015; Haroutiunian et  al.,  2013). The percentage of 
patients presenting signs suggestive of neuropathic pain is 
even less (Haroutiunian et al., 2013). In most preclinical an-
imal models of neuropathic pain, almost all animals exhibit 
behaviours suggesting of hyperalgesia and allodynia. The 
same is true for animal models of musculoskeletal (arthri-
tis) pain. Therefore, the findings from these animal models 
might not translate well to the mechanisms of chronic pain 
in patients and prevention strategies based on these studies 
might therefore fail. Only very few preclinical models were 
able to address this issue. One example for postsurgical pain 
is a model for evaluation of persistent post- thoracotomy pain 
(Buvanendran et al., 2004). Here, approximately half of the 
animals developed long- lasting signs suggestive of hyperal-
gesia after surgery, and reminiscent of clinical observations 
(Haroutiunian et  al.,  2013). Similar, signs of persistent in-
creased sensitivity to mechanical stimulation at the joint after 
antigen- induced arthritis (AIA) was only found in a subgroup 
of rats (Leuchtweis et al., 2020). These models are disease- 
related as well as mechanisms- based and should therefore be 
preferred for translational research in order to identify pre-
ventive targets relevant for disease specific chronification of 
pain. However, using these models in preclinical studies to 
investigate mechanisms related to the development of per-
sistent pain and preventive strategies are rare. In addition, 
translation is still required to prove that treatments targeting 
these mechanisms potentially prevent chronification of pain 
in humans (Martinez et  al.,  2017; Weinstein et  al.,  2018). 
Preventive translational approaches with drugs are not very 
numerous, but these bring a very valuable guide for chronic 
pain treatment, as has been developed with NMDA antag-
onists in animals, healthy volunteers and patients (Martin 
et al., 2019; Morel et al., 2013, 2016). In addition, an interdis-
ciplinary approach is needed because molecular, psychologi-
cal, social and therapeutic aspects influence the development 
of chronic pain. There is still a long way to go before we 
know what combination of factors is beneficial for the pre-
vention of pain, and the duration and types of treatments re-
quired. Understanding what patients respond to which kind 
of preventive strategy, and coupling this with translational 
approaches, may add valuable knowledge.
8 |  CONCLUSION
This opinion paper brings together pain researchers from 
very different disciplines to discuss the opportunities within, 
and challenges of, translational pain research. Examples are 
provided in Figure 2 illustrating some components of trans-
lational pain research. The many reasons that can prevent 
the successful translation of bench observations into useful 
and effective clinical applications are reviewed. Different ex-
ploratory paths can address these issues and include (1) the 
backward translation of observations made in patients and 
human volunteers into new disease models with improved 
clinical relevance, (2) improved generalizability by taking 
into account age and sex differences, and (3) the integration 
of psychobiology into translational pain research. Moreover, 
preclinical and clinical stages of developing new treatments 
for pain can be improved by better preclinical models of 
pathological pain conditions, and improved methods to assess 
treatment- induced effects on pain perception and nociceptive 
processing in humans and non- human animals, respectively. 
Finally, persistence of pain involves plasticity in the periph-
eral and central nervous system. It is therefore likely that suc-
cessful outcome of a treatment given at a particular time in 
preclinical research will not be efficacious at all stages of 
disease initiation, progression and maintenance in patients. 
Future research should thus probably take into consideration 
the dynamics of the mechanisms as they evolve over time.
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